Latest & greatest articles for doxazosin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on doxazosin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on doxazosin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for doxazosin

1. Doxazosin

Doxazosin Top results for doxazosin - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for doxazosin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

2. [Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. (PubMed)

[Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. 26948046 2017 08 08 2018 12 02 1578-8865 42 7 2016 10 Semergen Semergen [Spironolactone versus placebo, bisoprolol and doxazosin to determine the optimal treatment for drug-resistant hypertension]. e108-e109 S1138-3593(16)00049-6 10.1016/j.semerg.2016.01.017 Divisón Garrote J A JA Atención Primaria, Centro de Salud Casas Ibáñez, Casas-Ibáñez, Albacete, España (...) ; Universidad Católica San Antonio de Murcia, Murcia, España. Electronic address: jadivison@telefonica.net. Escobar Cervantes C C Servicio de Cardiología, Hospital La Paz, Madrid, España. spa Journal Article Comment Espironolactona versus placebo, bisoprolol y doxazosina para determinar el tratamiento óptimo de hipertensión resistente a fármacos. 2016 03 03 Spain Semergen 9610769 1138-3593 0 Antihypertensive Agents 27O7W4T232 Spironolactone NW1291F1W8 Doxazosin Y41JS2NL6U Bisoprolol IM Lancet. 2015 Nov

2017 Semergen Controlled trial quality: uncertain

3. ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. (PubMed)

ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. 26882301 2016 06 14 2018 12 02 1539-3704 164 4 2016 Feb 16 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. In resistant hypertension, add-on spironolactone reduced SBP more than placebo, doxazosin, or bisoprolol over 12 wk. JC16 10.7326/ACPJC-2016-164-4-016 Rosenberg Mark M Stephens Elizabeth E eng Journal Article Comment United States Ann Intern (...) Med 0372351 0003-4819 0 Adrenergic alpha-1 Receptor Antagonists 0 Adrenergic beta-1 Receptor Antagonists 0 Mineralocorticoid Receptor Antagonists 27O7W4T232 Spironolactone NW1291F1W8 Doxazosin Y41JS2NL6U Bisoprolol AIM IM Lancet. 2015 Nov 21;386(10008):2059-68 26414968 Adrenergic alpha-1 Receptor Antagonists therapeutic use Adrenergic beta-1 Receptor Antagonists therapeutic use Bisoprolol therapeutic use Doxazosin therapeutic use Female Humans Hypertension drug therapy Male Mineralocorticoid

2016 Annals of Internal Medicine Controlled trial quality: uncertain

4. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. (PubMed)

Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. Given the favorable impact of α1-blockers on lipid and glucose metabolism, this study was designed to compare the efficacy of two extended-release α1-blockers (bunazosin and doxazosin) as an add-on treatment in subjects with stage 1 or 2 essential hypertension which (...) was inadequately controlled by valsartan 80 mg/day.After a 5-week treatment of valsartan monotherapy, subjects with inadequately controlled hypertension were randomized to receive either extended-release bunazosin (n = 47) or doxazosin (n = 46) after breakfast for 8 weeks. Office sitting blood pressure (BP), 24-hour ambulatory BP, and metabolic profiles were measured at baseline, start of study drug, and study end.In the intention-to-treat population (n = 93), the average daily doses of bunazosin

2016 Zhonghua Minguo xin zang xue hui za zhi = Acta Cardiologica Sinica Controlled trial quality: uncertain

5. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia

An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia McDonald H, Hux M, Brisson M, Bernard L, Nickel J C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined finasteride (FIN), a 5-alpha-reductase inhibitor, either alone or in combination with doxazosin (DOX), an alpha-blocker, for the treatment of benign prostate hyperplasia (BPH). The doses used were 5 mg FIN once daily and 4 mg DOX once daily. Type

2004 NHS Economic Evaluation Database.

6. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. (PubMed)

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown.We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving 3047 men to compare the effects (...) of placebo, doxazosin, finasteride, and combination therapy on measures of the clinical progression of benign prostatic hyperplasia.The risk of overall clinical progression--defined as an increase above base line of at least 4 points in the American Urological Association symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection--was significantly reduced by doxazosin (39 percent risk reduction, P<0.001) and finasteride (34 percent risk

Full Text available with Trip Pro

2003 NEJM Controlled trial quality: uncertain

7. The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy

The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy Casciano J, Doyle J, Casciano R, Kopp Z, Marchant N, Bustacchini S, Arikian S, Kim R Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of doxazosin for the treatment of hypertension in Type II diabetes. Type of intervention Treatment and prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with Type II

2001 NHS Economic Evaluation Database.

8. New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®)

New Drugs VI ? Rosiglitazone (Avandia®), Tolterodine (Detrol®), Bupropion (Wellbutrin SR®, Zyban®), Doxazosin (Cardura®) [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin | Therapeutics Initiative Independent Healthcare Evidence > > [44] New Drugs VII – Mirtazapine (Remeron®), Salmon-Calcitonin Nasal Spray (Miacalcin®), Gatifloxacin (Tequin®), Moxifloxacin Mirtazapine (Remeron ® ) Approved indication: “Symptomatic

2000 Therapeutics Letter

9. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. (PubMed)

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. Hypertension is associated with a significantly increased risk of morbidity and mortality. Only diuretics and beta-blockers have been shown to reduce this risk in long-term clinical trials. Whether newer antihypertensive agents reduce the incidence of cardiovascular disease (...) (CVD) is unknown.To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril.Randomized, double-blind, active-controlled clinical trial, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, initiated in February 1994. In January 2000, after an interim analysis, an independent data

2000 JAMA Controlled trial quality: predicted high